GSK-3 Inhibitors: Discoveries and Developments

Author(s): M. Alonso, A. Martinez

Journal Name: Current Medicinal Chemistry

Volume 11 , Issue 6 , 2004

Become EABM
Become Reviewer


Glycogen synthase kinase 3 (GSK-3) in the 21st century emerged as one of the most attractive therapeutic target for the development of selective inhibitors as new promising drugs for unmet pathologies including Alzheimers disease, stroke, bipolar disorders, chronic inflammatory processes, cancer and diabetes type II. The full potential of GSK-3 inhibitors is just starting to be realized but the number of candidates in development provided by both academic centres and pharmaceutical companies have increased exponentially in the last two years. This review discloses recent discoveries and developments on peptides and small molecules targeting GSK-3. Focusing attention on this exciting target could thus reap considerable clinical and economic rewards.

Keywords: gsk-3 inhibitors, diabetes type II, neurodegenerative diseases, tau protein

Rights & PermissionsPrintExport Cite as

Article Details

Year: 2004
Page: [755 - 763]
Pages: 9
DOI: 10.2174/0929867043455738
Price: $65

Article Metrics

PDF: 5